Top 3 Picks
2026 Outlook
Sector trends through 2026 center on expanding adoption of liquid biopsies and AI-enhanced pathology, supported by improving reimbursement for multi-cancer early detection and genetic screening. Growth is projected in the mid-teens as companies scale international operations and integrate new assays in oncology and women's health. Headwinds from regulatory scrutiny and payer negotiations may moderate margins but are unlikely to derail overall expansion.
Complete Rankings
| Rank | Stock | Score | Price | Market Cap |
|---|---|---|---|---|
|
1
|
Veracyte, Inc.
|
59.7 | $42.53 | $2.8B |
|
2
|
Exact Sciences Corp
|
59.1 | $104.91 | $10.7B |
|
3
|
Fulgent Genetics, Inc. Common Stock
|
54.6 | $19.73 | $719M |
|
4
|
Quest Diagnostics Inc.
|
52.6 | $237.14 | $20.4B |
|
5
|
Fortrea Holdings Inc. Common Stock
|
52.5 | $17.70 | $864M |
|
6
|
RadNet, Inc. Common Stock
|
51.5 | $73.71 | $6.0B |
|
7
|
Labcorp Holdings Inc.
|
50.9 | $326.89 | $23.2B |
|
8
|
GRAIL, Inc. Common Stock
|
50.3 | $80.34 | $2.2B |
|
9
|
Guardant Health, Inc. Common Stock
|
50.1 | $161.41 | $7.8B |
|
10
|
Natera, Inc. Common Stock
|
49.0 | $328.18 | $22.2B |
|
11
|
Celcuity Inc. Common Stock
|
45.6 | $95.70 | $1.9B |
|
12
|
Personalis, Inc. Common Stock
|
41.1 | $17.20 | $613M |
|
13
|
Castle Biosciences, Inc. Common Stock
|
37.9 | $32.91 | $668M |
|
14
|
Caris Life Sciences, Inc. Common Stock
|
37.6 | $25.07 | $8.5B |
|
15
|
CareDx, Inc.
|
35.7 | $50.88 | $798M |
In-Depth Analysis: Top Medical Labs Stocks
VCYT
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run …
Veracyte, Inc. matters in the Medical Labs sector through its genomic diagnostic tests including Decipher Prostate, Afirma for thyroid cancer, and Prosigna for breast cancer, which deliver molecular insights to guide clinician decisions at key cancer diagnosis and treatment points.
Veracyte reports a 20.4% profit margin and 15.5% revenue growth alongside an 8.8% ROE, indicating solid margins and top-line expansion in genomic testing offset by moderate equity returns.
Investors should consider VCYT in 2026 as its 15.5% revenue growth and 20.4% profit margin support scalable adoption of oncology genomic tests amid rising cancer caseloads. A P/E of 31.9 embeds expectations for continued diagnostic volume gains in prostate, thyroid, and breast segments. The Tradestie Score of 59.7/100 reflects a balanced risk-reward profile for sector exposure.
EXAS
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy …
Exact Sciences matters in the Medical Labs sector through its Cologuard noninvasive stool-based DNA test for colorectal cancer screening and its competing position in precision oncology, serving critical early-detection needs across U.S. and international markets.
Exact Sciences reports a -6.4% profit margin and -8.7% ROE, reflecting ongoing net losses, yet its 23.1% revenue growth demonstrates expanding adoption of core diagnostic products amid continued investment.
Despite current losses, Exact Sciences' 23.1% revenue growth positions the company for margin expansion by 2026 as Cologuard volumes scale and precision oncology offerings mature. International market penetration and rising colorectal screening demand could lift profitability above the -6.4% margin level. At a Tradestie Score of 59.1/100, the stock offers growth investors exposure to a leading cancer diagnostics platform with improving financial leverage.
FLGT
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused …
Fulgent Genetics delivers genetic testing services that supply physicians with clinically actionable diagnostic data, positioning it as a specialized player in the Medical Labs sector focused on precision medicine and laboratory services.
Fulgent Genetics reports a -26.1% profit margin and -8.1% ROE, reflecting ongoing losses and weak returns on equity, while its 4.4% revenue growth shows limited top-line momentum in the laboratory services segment.
Investors may consider FLGT in 2026 as its therapeutic development business and core lab services expand amid rising demand for genetic diagnostics, potentially lifting margins above the current -26.1% level. The Tradestie Score of 54.6/100 provides a moderate baseline for operational recovery, with revenue growth at 4.4% offering a foundation for scaling in a growing precision medicine market.
DGX
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs …
Quest Diagnostics leads the Medical Labs sector as the largest independent US provider of diagnostic testing, generating over 95% of revenue from clinical testing, anatomic pathology, esoteric testing, and substance abuse testing through its national network.
Quest reports a 9.2% profit margin and 14.6% ROE with 10.2% revenue growth, reflecting efficient operations and solid financial health at a P/E of 25.4.
DGX offers investors exposure to essential diagnostic demand projected to expand through 2026, supported by 10.2% revenue growth and 14.6% ROE that demonstrate scalable testing volume and capital efficiency. Its dominant network position in clinical and esoteric testing positions the company to capture incremental market share in a sector with recurring revenue streams. At a P/E of 25.4, the valuation provides a reasonable entry point relative to earnings growth for a stable healthcare provider.
FTRE
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an …
Fortrea Holdings Inc. serves as a key global contract research organization in the Medical Labs sector, delivering phase 1-4 clinical trial management and pharmacology solutions to biopharma, medical device, and diagnostic firms.
Fortrea reports a -3.2% profit margin and -15.3% ROE alongside -4.5% revenue growth, reflecting persistent unprofitability and contraction in top-line performance.
Fortrea's established platform in late-stage trials positions it to capture rising biopharma outsourcing demand by 2026. Operational efficiencies could reverse the current -3.2% margin and -4.5% revenue decline, supporting earnings recovery. At a Tradestie Score of 52.5, the stock offers potential upside for investors targeting sector consolidation and clinical services expansion.
RDNT
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic …
RadNet, Inc. operates as a national provider of diagnostic imaging services through its Imaging Center and Digital Health segments, enabling physicians to diagnose and treat diseases across the Medical Labs sector.
RadNet reports a -0.9% profit margin and 1.5% ROE, indicating thin current profitability and low equity returns, while its 25.0% revenue growth reflects operational expansion that may support future margin recovery.
RadNet's 25.0% revenue growth positions the company for scaled operations in diagnostic imaging and digital health by 2026. Rising demand for imaging services amid an aging population could drive margin expansion from current levels. National footprint and segment diversification offer a pathway to improved ROE and sustained top-line momentum.
LH
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Labcorp holds roughly 20% of the U.S. independent clinical lab market as one of the two largest players, operating 2,000 patient service centers and delivering 5,000 tests spanning routine diagnostics to complex assays.
The company reports a 7.0% profit margin and 11.7% ROE alongside 5.8% revenue growth, indicating moderate profitability and returns, while the 27.4 P/E ratio and 50.9/100 Tradestie Score reflect a valuation premium relative to current earnings growth.
Sustained 5.8% revenue expansion and 20% market share position Labcorp to capture rising demand for diagnostic testing through 2026. A 11.7% ROE supports capital allocation for network expansion across 2,000 centers, potentially lifting margins above 7.0%. At a 27.4 P/E, the stock offers entry for investors seeking exposure to scaled lab infrastructure amid healthcare utilization trends.
GRAL
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
GRAIL Inc matters in the Medical Labs sector as a developer of multi-cancer early detection (MCED) blood tests capable of identifying all cancer types across stages, operating in a single segment focused on advancing early intervention diagnostics.
GRAIL reports a -236.9% profit margin and -16.1% ROE, reflecting heavy investment in R&D and commercialization that sustains deep losses despite 25.7% revenue growth.
Investors should consider GRAIL for 2026 given its 25.7% revenue expansion and potential for MCED test adoption to accelerate with regulatory milestones, which could narrow losses from the current -236.9% margin. The Tradestie Score of 50.3/100 indicates baseline viability that may improve if scale efficiencies lift ROE above -16.1% and position the company as a leader in high-growth cancer screening.
GH
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched …
Guardant Health leads the Medical Labs sector through its liquid biopsy platform, with Guardant360 LDT and FDA-approved Guardant360 CDx enabling non-invasive treatment selection for advanced-stage cancers.
Guardant Health reports a -38.3% profit margin and -4584.5% ROE, reflecting deep operating losses and negative equity returns, even as revenue grew 44.3%.
Revenue expansion at 44.3% positions Guardant to scale its liquid biopsy offerings into larger oncology markets by 2026. FDA clearances and clinical adoption could drive operating leverage that narrows the current -38.3% margin. A Tradestie Score of 50.1/100 leaves room for re-rating if growth sustains and cash burn moderates.
NTRA
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number …
Natera leads in the Medical Labs sector through its Panorama NIPT, which employs proprietary molecular and bioinformatics technology to screen for fetal chromosomal abnormalities in singleton and twin pregnancies, capturing a growing share of the non-invasive prenatal diagnostics market.
Natera reports a -7.1% profit margin and -12.5% ROE, reflecting current unprofitability driven by R&D and commercialization spend, yet this is offset by 37.7% revenue growth that signals expanding test volumes and market penetration.
Natera's 37.7% revenue growth supports a path to margin expansion and positive ROE by 2026 as fixed costs dilute across higher volumes in prenatal and oncology testing. Scaling of its bioinformatics platform could drive operating leverage, improving the -7.1% profit margin toward breakeven. At a Tradestie Score of 49.0/100, the stock offers entry for investors targeting diagnostic sector consolidation and test-menu expansion.
Methodology
Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.